US Benign Prostatic Hyperplasia (BPH) Procedures t

NEW YORK, Sept. 26, 2017 (GLOBE NEWSWIRE) -- According to new market research report titled “ US Benign Prostatic Hyperplasia (BPH) Procedures by Type (Green Light Lasers, Holmium Lasers, Thulium Lasers, TURP, TUIP, TUMT, TUNA, Rezūm, HIFU & Water Induced Therapies, UroLift) – Procedures, Development, Growth and Forecast, 2013-2023 ” published by P&S Market Research, the U.S. Benign Prostatic Hyperplasia (BPH) Procedures is expected to grow at a CAGR of 4.2% during 2017 – 2023

Increase in the aging population in the U.S in the next few years, is expected to create high demand for BPH treatments, since the population aged 50 years and above is more prone to BPH, and therefore tend to opt for various treatments that involve the use of procedures such as TURP, TUIP and laser based treatments. According to the National Institute of Health, it has been estimated that around 14 million men in the U.S. had symptoms suggestive of BPH, which can affect 50% of men aged between 51 and 60 years of age, and up to 90% of men aged more than 80 years. With 50% of men getting affected with BPH, there is a consequent increase in the BPH procedures.

The advanced research and development activities has led to the development of technologically advanced BPH devices and therapies. Prostatic urethral lift (Urolift system) and targeted sterile water vapor therapy (Rezūm) are some of the recent technological therapies launched for BPH management. Rezūm is a minimally invasive procedure that uses steam in the treatment of enlarged prostate and is currently available in the U.S. These therapies can be performed in a clinic or at an outpatient facility, and thereby reduce the cost associated with hospital stay and surgeries.

Access Detailed Report Summary on "US Benign Prostatic Hyperplasia (BPH) Procedures" at: https://www.psmarketresearch.com/market-analy...procedures

As per the findings of the research, the different type of BPH treatment procedure include laser based procedures, surgical procedures, UroLift and other energy based procedures. Laser based procedures is expected to account for the largest share in the U.S. BPH procedures during the forecast period, since these procedures are more effective, as compared to the conventional procedures and are less likely to cause bleeding and other complications. Urolift is projected to register the fastest growth during the forecast period, mainly driven by the aging U.S. population, expanding insurance coverage of the procedure by various insurers, low cost of the procedure, and possibility of indication expansion of the UroLift procedure for the treatment of patients with BPH who have an obstructive median lobe.

Key player in the U.S. BPH procedures are acquiring other players to offer advanced products for BPH treatment procedures. For instance, in September 2017, Teleflex Incorporated, announced that the company has entered into definitive agreement with NeoTract, Inc. Under the terms of the agreement, Teleflex Incorporated agreed to acquire NeoTract, Inc. for a consideration of up to $1.1 billion. With this agreement, Teleflex Incorporated would be able to leverage the potential long-term benefits from NeoTracts, Inc. second generation UroLift system, which is expected to launch in the mid of 2018.

Some of the other key players providing products for BPH procedures in the U.S. include NxThera, Inc., Boston Scientific Corporation, Urologix, LLC., Convergent Laser Technologies.

Related Research Reports

Global Benign Prostatic Hyperplasia (BPH) Procedures

Geographically, Europe accounted for the largest number of BPH procedures done in 2016. Growing ageing population, lower cost of BPH treatment as compared to the U.S., high healthcare spending, and technological advancements in the field of urological procedures technology are some of the factors driving the growth of the BPH procedures in the Europe. France, Germany and the U.K. are expected to be the most promising countries for the growth in number of the BPH procedures. In June 2016, National Institute of Health and Care Excellence (NICE) approved GreenLight XPS laser treatment for the treatment of BPH. NICE added that the widespread adoption of the procedure could save the National Health Services (NHS) an estimated $4.3 million (£3 million) a year. Asia-Pacific is expected to witness the high number of BPH procedures performed during the forecast period, owing to the rising prevalence of BPH disorders, increasing disposable income, aging population, and growing efforts to increase awareness about advanced BPH treatment procedures.

  https://www.psmarketresearch.com/market-analy...procedures

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact: Abhishek 347, 5th Ave. #1402 New York City, NY - 10016 Toll-free: +1-888-778-7886 (USA/Canada) Email:   enquiry@psmarketresearch.com Web:   https://www.psmarketresearch.com Connect with us: LinkedIn | Twitter | Google + | Facebook